HeliosX, the London-based online pharmacy, has made significant strides in the weight-loss drug market, recently boasting a remarkable reduction of 8.5 million kilograms in patient weight, equating to approximately 3.5
Weightloss
41Articles
Novo Nordisk, Denmark’s leading pharmaceutical company known for its weight management medications, has encountered significant economic hurdles recently. After achieving initial success with its medications Wegovy and Ozempic, the company
Novo Nordisk, the Danish pharmaceutical giant, has entered a significant partnership with Vivtex, a biotech startup co-founded by renowned entrepreneur Robert Langer, to develop innovative oral formulations of its obesity
A head-to-head trial of Novo Nordisk’s next-generation obesity drug, CagriSema, has revealed disappointing results in comparison to rival Eli Lilly’s Mounjaro. The trial results have triggered a significant sell-off in
In a revealing analysis, Jefferies has indicated that the increasing popularity of weight-loss medications may pose significant challenges for Greggs, the UK bakery chain. As consumers turn to drugs such
Weight-loss drugs have experienced a remarkable rise in the UK since their approval in 2023. As many as 1.5 million Britons are now reported to be using GLP-1 medications for
Weightloss medications are poised to profoundly impact the operational expenses of airlines in the United States, potentially leading to savings of hundreds of millions of pounds annually. Analysts from Jefferies,
Novo Nordisk has introduced the first oral formulation of its blockbuster GLP-1 weight loss medication to the United States market, marking a significant shift in the pharmaceutical landscape for obesity
The Danish pharmaceutical giant Novo Nordisk initiated a revolution in weight management with its groundbreaking therapies Ozempic and Wegovy. However, the company now faces a period of substantial upheaval following
Marks and Spencer has unveiled a specialised food range designed for consumers taking GLP-1 weight-loss medications, marking a significant retail adaptation to the pharmaceutical trend reshaping consumer behaviour across the
Novo Nordisk has secured a significant regulatory victory, following the United States Food and Drug Administration’s approval of its new weight loss pill containing semaglutide. The decision delivers the Danish
The UK faces a surge in counterfeit weight loss injections as criminal groups target a lucrative and vulnerable market. Recent warnings from the pharmaceutical sector highlight an exponential rise in
Illicit Weight Loss Drug Supplier Alluvi Persists with Unlicensed Sales After High Profile MHRA Raid
A company linked to the globe’s largest known seizure of illicit weight-loss medications remains active in the UK market despite regulatory intervention. Alluvi, the firm in question, continues to distribute
A recent investigation has brought to light the troubling prevalence of illegal weight loss drug sales in the United Kingdom, with certain businesses exploiting online review platforms such as Trustpilot
In a landmark development underscoring the global race for obesity treatments, US pharmaceutical giant Pfizer has secured a ten billion dollar takeover of Metsera. The deal follows an intense bidding
Danish pharmaceutical giant Novo Nordisk has revised its profit forecasts downwards for the fourth time this year as competition in the slimming and diabetes treatments market continues to grow. The
